Cardiovascular Systems Sponsoring Lunch Symposium on Arterial Calcium at 2013 VIVA Conference Company Also Featuring Hands-on Cadaver Mobile Lab Training Session Business Wire ST. PAUL, Minn. -- October 2, 2013 Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), is sponsoring a lunch symposium highlighting the challenges and treatment options for Peripheral Arterial Disease complicated by calcium at the 2013 Vascular Interventional Advances (VIVA) conference in Las Vegas, Oct. 8-11, 2013. In order to enhance this learning opportunity, CSI will also host a hands-on training session in its mobile lab using cadavers to train attendees on pedal access and the use of orbital atherectomy. CSI-Sponsored Lunch Symposium: Oct. 10 WHAT: Industry leaders will share their expertise on issues related to the treatment of arterial calcium during a lunch symposium sponsored by CSI. The symposium, titled “Arterial Calcium: Challenges and Treatments,” will cover the implications of calcium in device selection, treatment options and outcomes with orbital atherectomy. It will address treatment techniques in complex cases as well as the limitations and considerations of emerging drug-coated and bioresorbable platforms. The symposium will be moderated by John Rundback, MD, Holy Name Medical Center, Teaneck, N.J. TOPICS: Prevalence of Calcium and Implications for Infrapopliteal -- Device Selection – Lawrence Garcia, MD, St. Elizabeth’s Medical Center, Brighton, Mass. Clinical Outcomes of OAS Treatment Options for -- Infrapopliteal Patients – John Rundback, MD, Holy Name Medical Center, Teaneck, N.J. Simple Techniques for Complex Cases – Arthur Lee, MD, -- Cardiac & Vascular Institute, Lake City Medical Center, North Florida Regional Medical Center, Gainesville, Fla. Limitations of Current Drug Eluting and Bioresorbable -- Technologies – Biological Considerations for Future Device Selection – Thomas Zeller, MD, University Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany -- Panel Discussion WHEN: Thursday, Oct. 10, 12:00 – 1:15 p.m. WHERE: Lafite 7, Wynn Las Vegas 3131 Las Vegas Blvd. S. Las Vegas, NV 89109 Mobile Training Lab: Oct. 10 WHAT: CSI will host a cutting-edge, hands-on cadaver lab at VIVA, featuring ultrasound guided tibial and pedal access followed by orbital atherectomy treatment. WHEN: Thursday, Oct. 10, 5:30 p.m. WHERE: Mouton 2, Wynn Las Vegas 3131 Las Vegas Blvd. S. Las Vegas, NV 89109 CSI Booth at VIVA: Oct. 8–10 Visit CSI at booth #406, 7 a.m. – 4:15 p.m., Tuesday, Oct. 8; Wednesday, Oct. 9; and Thursday, Oct. 10. About Peripheral Arterial Disease (PAD) PAD is a life-threatening condition where a fatty material called plaque builds up on the inside walls of the blood vessels that carry blood from the heart to legs and arms. The plaque buildup causes the arteries to harden and narrow (atherosclerosis), reducing blood flow to the legs. The risk of PAD increases if a person has one or several of the following: high blood pressure, abnormal cholesterol levels, diabetes, or personal history of heart disease, heart attack or stroke. PAD affects an estimated 8-12 million people in the United States. The disease prevalence increases with age and 12-20 percent of Americans age 65 and older suffer from PAD symptoms. As the U.S. population ages, the prevalence range could reach 16 million in those age 65 and older and 19 million overall by 2050. About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital Atherectomy System in August 2007. To date, nearly 110,000 of CSI’s devices have been sold to leading institutions across the United States. CSI has also completed its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its orbital technology in treating coronary arteries. The coronary system is limited by federal law to investigational use and is currently not commercially available in the United States. For more information, visit the company’s website at www.csi360.com. Contact: For Cardiovascular Systems, Inc. Investor Relations, 651-259-2800 email@example.com or Sarah Wozniak, 651-259-1636 firstname.lastname@example.org or PadillaCRT: Matt Sullivan, 612-455-1709 email@example.com or Dave Folkens, 612-455-1741 firstname.lastname@example.org
Cardiovascular Systems Sponsoring Lunch Symposium on Arterial Calcium at 2013 VIVA Conference
Press spacebar to pause and continue. Press esc to stop.